Apelin-13 Administration Protects Against Ischaemia/reperfusion-mediated Apoptosis Through the FoxO1 Pathway in High-fat Diet-induced Obesity
Overview
Authors
Affiliations
Background And Purpose: Apelin-13, an endogenous ligand for the apelin (APJ) receptor, behaves as a potent modulator of metabolic and cardiovascular disorders. Here, we examined the effects of apelin-13 on myocardial injury in a mouse model combining ischaemia/reperfusion (I/R) and obesity and explored their underlying mechanisms.
Experimental Approach: Adult male C57BL/6J mice were fed a normal diet (ND) or high-fat diet (HFD) for 6 months and then subjected to cardiac I/R. The effects of apelin-13 post-treatment on myocardial injury were evaluated in HFD-fed mice after 24 h I/R. Changes in protein abundance, phosphorylation, subcellular localization and mRNA expression were determined in cardiomyoblast cell line H9C2, primary cardiomyocytes and cardiac tissue from ND- and HFD-fed mice. Apoptosis was evaluated by TUNEL staining and caspase-3 activity. Mitochondrial ultrastructure was analysed by electron microscopy.
Key Results: In HFD-fed mice subjected to cardiac I/R, i.v. administration of apelin-13 significantly reduced infarct size, myocardial apoptosis and mitochondrial damage compared with vehicle-treated animals. In H9C2 cells and primary cardiomyocytes, apelin-13 induced FoxO1 phosphorylation and nuclear exclusion. FoxO1 silencing by siRNA abolished the protective effects of apelin-13 against hypoxia-induced apoptosis and mitochondrial ROS generation. Finally, apelin deficiency in mice fed a HFD resulted in reduced myocardial FoxO1 expression and impaired FoxO1 distribution.
Conclusions And Implications: These data reveal apelin as a novel regulator of FoxO1 in cardiac cells and provide evidence for the potential of apelin-13 in prevention of apoptosis and mitochondrial damage in conditions combining I/R injury and obesity.
The Apelin/APJ System: A Potential Therapeutic Target for Sepsis.
Song Q, Wang X, Cao Z, Xin C, Zhang J, Li S J Inflamm Res. 2024; 17:313-330.
PMID: 38250143 PMC: 10800090. DOI: 10.2147/JIR.S436169.
Modulating Stress Proteins in Response to Therapeutic Interventions for Parkinson's Disease.
Silvestro S, Raffaele I, Mazzon E Int J Mol Sci. 2023; 24(22).
PMID: 38003423 PMC: 10671288. DOI: 10.3390/ijms242216233.
Rossin D, Vanni R, Lo Iacono M, Cristallini C, Giachino C, Rastaldo R Pharmaceutics. 2023; 15(5).
PMID: 37242650 PMC: 10223849. DOI: 10.3390/pharmaceutics15051408.
Respekta N, Pich K, Dawid M, Mlyczynska E, Kurowska P, Rak A Cells. 2023; 12(1).
PMID: 36611944 PMC: 9818302. DOI: 10.3390/cells12010150.
Winkle P, Goldsmith S, Koren M, Lepage S, Hellawell J, Trivedi A Cardiovasc Drugs Ther. 2022; 37(4):743-755.
PMID: 35460392 DOI: 10.1007/s10557-022-07328-w.